Clincosm LogoSign in Get a demo

Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)

Sponsor
Hemera Biosciences (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT04358471
Collaborator
(none)
0
Enrollment
3
Arms
25
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Patients with advanced dry AMD with GA meeting inclusion criteria will be randomized in one eye in a 1:1:1 ratio comparing intravitreal high or low dose AAVCAGsCD59 with a sham injection. All enrolled subjects will be followed for 24 months to evaluate reduction in GA growth and safety of intravitreal AAVCAGsCD59.

Condition or Disease Intervention/Treatment Phase
  • Biological: Intravitreal AAVCAGsCD59
  • Other: Intravitreal Sham Injection
 Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Subjects will be assigned to low dose AAVCAGsCD59, high dose AAVCAGsCD59, or sham arm.Subjects will be assigned to low dose AAVCAGsCD59, high dose AAVCAGsCD59, or sham arm.
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Phase 2 Multi-Center Trial Evaluating Intravitreal AAVCAGsCD59 Compared to Sham Injection for the Treatment of Advanced Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Anticipated Study Start Date :
Jul 31, 2021
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Intravitreal AAVCAGsCD59 1.071x10e12 vg Injection

Intravitreal AAVACGsCD59 at a dose of 1.071x10e12 vg administered once on Day 0

Biological: Intravitreal AAVCAGsCD59
AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye
Other Names:
  • HMR59

    		•
    Active Comparator: Intravitreal AAVCAGsCD59 3.56x10e11 vg Injection

    Intravitreal AAVACGsCD59 at a dose of 3.56x10e11 vg administered once on Day 0

    Biological: Intravitreal AAVCAGsCD59
    AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye
    Other Names:
  • HMR59

    		•
    Sham Comparator: Sham Intravitreal Injection

    Intravitreal Sham injection administered once on Day 0

    Other: Intravitreal Sham Injection
    Sham injection mimics a real injection in the enrolled eye
    Other Names:
  • Sham

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Evaluate the change in Geographic Atrophy area (mm2) measured at Day 0 and compared to the measurement at Month 24 [24 Months]

      Geographic atrophy will be measured based on imaging of the retina

    Secondary Outcome Measures

    1. Incidence of conversion from dry to wet age-related macular degeneration [24 Months]

      Measure the number of treated eyes in the sham and AAVCAGsCD59-treated arms that convert from dry to wet age-related macular degeneration

    2. Change in visual acuity of the AAVCAGsCD59 treated eye [24 Months]

      Visual acuity measured on an Early Treatment Diabetic Retinopathy Study (ETDRS) chart will be compared at Day 0 and Month 24

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    65 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Advanced dry AMD with GA in the study eye

    2. BCVA in the study eye of 80 or less ETDRS letters (Snellen equivalent 20/25 or worse)

    3. Total cumulative GA lesion size 2.5 mm2 to 12.5 mm2 in the study eye as confirmed by the reading center during the Screening Period.

    Exclusion Criteria:

    1. GA secondary to non-AMD etiologies in the study eye (i.e. myopia, inherited retinal diseases).

    2. GA associated with the presence of an RPE rip.

    3. GA contiguous with peripapillary atrophy.

    4. Active CNV secondary to wet AMD in the study eye and currently receiving anti-VEGF ocular treatment within the previous 18 months.

    5. Subretinal fibrosis in the macula from CNV both clinically and imaged on SD-OCT in the macula.

    6. Previous macular laser photocoagulation (i.e. focal or grid laser for macular edema), photodynamic therapy (PDT), ocular/orbital radiation, laser to CNV, or subretinal surgery for CNV in the study eye.

    7. History of conditions in the study eye which might alter visual acuity or interfere with study testing including proliferative diabetic retinopathy (PDR), clinically significant macular edema (CSME), central retinal vein occlusion (CRVO), hemi retinal vein occlusion (HRVO), macular branch retinal vein occlusion, and optic neuropathy.

    8. Active uncontrolled glaucoma with at least one of the following: IOP>30 mmHg despite maximum medical treatment with glaucoma medications, cup-to-disc ratio of >0.9, visual field defects secondary to glaucoma that involve the macula, or optic atrophy from glaucoma.

    9. Active acute or chronic infectious uveitis, retinitis, or conjunctivitis (excluding blepharitis)

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Hemera Biosciences

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hemera Biosciences
    ClinicalTrials.gov Identifier:
    NCT04358471
    Other Study ID Numbers:
    • HMR-2001
    First Posted:
    Apr 24, 2020
    Last Update Posted:
    May 10, 2021
    Last Verified:
    May 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Macular Degeneration
    Geographic Atrophy
    Atrophy

    Study Results

    No Results Posted as of May 10, 2021